Evaluation of the Efficacy of Topical Ophthalmic Steroids in a Modified Conjunctival Allergen Challenge (CAC) Model
Status:
Completed
Trial end date:
2008-06-01
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy of prednisolone acetate 1% ophthalmic suspension as compared to
prednisolone acetate 0.12% ophthalmic suspension, loteprednol etabonate 0.2% ophthalmic
suspension, and placebo (Tears Naturale® II) in the prevention of the signs and symptoms of
allergic conjunctivitis. Comparisons will be made following 1 week of twice daily (BID)
dosing and 1 week of four times daily (QID) dosing.